Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography
Top Cited Papers
- 19 May 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (12) , 4153-4160
- https://doi.org/10.1021/jm050155n
Abstract
In vivo imaging of dopamine D2 receptors with agonist (as opposed to the more commonly employed antagonist) radiotracers could provide important information on the high-affinity (functional) state of the D2 receptor in illnesses such as schizophrenia, movement disorders, and addictions. We report here the radiosynthesis and evaluation of the potent D2 agonist (+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, (+)-3, labeled with carbon-11, as a potential radiotracer for imaging the high-affinity state of dopamine D2 receptors with positron emission tomography (PET). [11C]-(+)-3 was reliably synthesized in the quantities and at the specific activities and radiochemical purities required for human PET studies. Ex vivo biodistribution studies in rat brain demonstrated that [11C]-(+)-3 crossed the blood−brain barrier readily and had an appropriate regional brain distribution for a radiotracer that maps dopamine D2 receptors. The binding of [11C]-(+)-3 was saturable and demonstrated an excellent signal-to-noise ratio as measured by its striatum-to-cerebellum ratio of 5.6, 60 min postinjection. The binding was highly stereospecific, and blocking and displacement studies were consistent with selective and specific binding to the dopamine D2 receptors. Further, [11C]-(+)-3 showed marked and appropriate sensitivity to both increases and decreases in the levels of endogenous dopamine. Brain radioactive metabolite and physicochemical measurements are in full accord with the desired properties of a neuroreceptor imaging agent for PET. All of the above, coupled with the documented full D2 agonistic properties of (+)-3, strongly indicate that [11C]-(+)-3 is a leading candidate radiotracer for the imaging of the dopamine D2 high-affinity state using PET in human subjects.Keywords
This publication has 34 references indexed in Scilit:
- In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐racloprideSynapse, 2004
- Constitutive activity of receptors coupled to guanine nucleotide regulatory proteinsPublished by Elsevier ,2002
- (−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptorsNuclear Medicine and Biology, 2000
- Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous InfusionJournal of Cerebral Blood Flow & Metabolism, 1997
- The Cubic Ternary Complex Receptor-Occupancy Model III. Resurrecting EfficacyJournal of Theoretical Biology, 1996
- Measurement of Benzodiazepine Receptor Number and Affinity in Humans Using Tracer Kinetic Modeling, Positron Emission Tomography, and [11C]FlumazenilJournal of Cerebral Blood Flow & Metabolism, 1993
- Synthesis and in vivo distribution in the rat of a dopamine agonist: N-([11C]methyl)norapomorphineNuclear Medicine and Biology, 1993
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- The dopamine agonist, phno ((+)-4-propyl-9-hydroxynaphthoxazine), inhibits cyclic adenosine 3', 5'-monophosphate formation and prolactin release from anterior pituitary cellsNeuropharmacology, 1989
- Mesoionic pyridazine ribonucleosides. A novel biologically active nucleoside metaboliteJournal of Medicinal Chemistry, 1984